{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:47:30Z","timestamp":1771519650404,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.prdoa.2022.100136","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T10:09:59Z","timestamp":1643450999000},"page":"100136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Parkinson\u2019s disease, treatment choice and survival over time"],"prefix":"10.1016","volume":"6","author":[{"given":"I.F.","family":"Tvete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Klemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2022.100136_b0005","doi-asserted-by":"crossref","unstructured":"C.J. Mayo, R.M. Sainz, D.X. Tan, I. Antol\u00edn, et al. Melatonin and Parkinson's Disease. Endocrine. 27. (2005). 169-78.","DOI":"10.1385\/ENDO:27:2:169"},{"key":"10.1016\/j.prdoa.2022.100136_b0010","doi-asserted-by":"crossref","unstructured":"R. Stowe, N. Ives, C. Clarke, et al. Meta-Analysis of the Comparative Efficacy and Safety of Adjuvant Treatment to Levodopa in Later Parkinson's Disease, Movement disorders: official journal of the Movement Disorder Society. 26. (2011). 587-598.","DOI":"10.1002\/mds.23517"},{"issue":"1","key":"10.1016\/j.prdoa.2022.100136_b0015","doi-asserted-by":"crossref","DOI":"10.1038\/srep45865","article-title":"Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis","volume":"7","author":"Zhuo","year":"2017","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100136_b0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000486252","article-title":"Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson\u2019s Disease: a Network Meta-Analysis","volume":"45","author":"Li","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.prdoa.2022.100136_b0025","doi-asserted-by":"crossref","unstructured":"C.D. Binde, I.F. Tvete, J.I. G\u00e5semyr, B. Natvig, M. Klemp. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease, British Journal of Clinical Pharmacology. 84(9). (2018). 1917- 1927. ISSN 0306-5251.","DOI":"10.1111\/bcp.13651"},{"issue":"12","key":"10.1016\/j.prdoa.2022.100136_b0030","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00228-020-02961-6","article-title":"Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson\u2019s disease \u2013 A multiple treatment comparison meta-analysis","volume":"76","author":"Binde","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"980","key":"10.1016\/j.prdoa.2022.100136_b0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad Med J"},{"issue":"1","key":"10.1016\/j.prdoa.2022.100136_b0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.29245\/2572.942X\/2019\/1.1241","article-title":"Treatment of Parkinson\u2019s Disease after the Wearing Off Sets in","volume":"4","author":"Mizuno","year":"2019","journal-title":"J Neurol Neuromed"},{"key":"10.1016\/j.prdoa.2022.100136_b0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2047-9158-4-4","article-title":"How to optimize the treatment of early stage Parkinson's disease","volume":"4","author":"Stocchi","year":"2015","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.prdoa.2022.100136_b0050","unstructured":"J. Jankovic, Therapeutic strategies in Parkinson\u2019s disease. In: J. Jankovic J, E. Tolosa, editors. Parkinson\u2019s Disease and Movement Disorders. 4. Philadelphia, PA: Lippincott Williams and Wilkins. (2002). 116\u2013151."},{"key":"10.1016\/j.prdoa.2022.100136_b0055","first-page":"53","article-title":"An update on the management of young-onset Parkinson's disease","volume":"2","author":"Klepac","year":"2013","journal-title":"Degener Neurol Neuromuscul Dis."},{"key":"10.1016\/j.prdoa.2022.100136_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/9952743","article-title":"Time until need for levodopa among new users of dopamine agonists or MAO-B inhibitors Parkinson\u2019s Disease","volume":"2021","author":"Binde","year":"2021","journal-title":"Parkinson\u2019s Disease"},{"key":"10.1016\/j.prdoa.2022.100136_b0065","unstructured":"The Norwegian Prescription Database: http:\/\/www.norpd.no\/."},{"key":"10.1016\/j.prdoa.2022.100136_b0070","unstructured":"The Norwegian Patient Registry: https:\/\/www.helsedirektoratet.no\/tema\/statistikk-registre-og-rapporter\/helsedata-og-helseregistre\/norsk-pasientregister-npr."},{"key":"10.1016\/j.prdoa.2022.100136_b0075","unstructured":"Regional committees for medical and health research ethics: https:\/\/rekportalen.no."},{"key":"10.1016\/j.prdoa.2022.100136_b0080","unstructured":"Akaike information criterion: https:\/\/www.statisticshowto.datasciencecentral.com\/akaikes-information-criterion\/."},{"key":"10.1016\/j.prdoa.2022.100136_b0085","unstructured":"https:\/\/www.rdocumentation.org\/packages\/stats\/versions\/3.6.1\/topics\/step\u201c."},{"key":"10.1016\/j.prdoa.2022.100136_b0090","unstructured":"R software: RStudio Team. (2020). RStudio: Integrated Development for R. RStudio, PBC, Boston, MA. URL http:\/\/www.rstudio.com\/."},{"key":"10.1016\/j.prdoa.2022.100136_b0095","doi-asserted-by":"crossref","unstructured":"R. Caslake, A. Macleod, N. Ives, et al. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database of Systematic Reviews. 4 (2009). Art. No.: CD006661. DOI: 10.1002\/14651858.CD006661.pub2.","DOI":"10.1002\/14651858.CD006661.pub2"},{"key":"10.1016\/j.prdoa.2022.100136_b0100","doi-asserted-by":"crossref","unstructured":"PD Med Collaborative Group, R. Gray, N. Ives, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. 27 (2014). 384(9949). 1196-1205. doi: 10.1016\/S0140-6736(14)60683-8. Erratum in: Lancet. 27. (2014). 384(9949). 1186. PMID: 24928805.","DOI":"10.1016\/S0140-6736(14)60683-8"},{"key":"10.1016\/j.prdoa.2022.100136_b0105","doi-asserted-by":"crossref","unstructured":"RA. Hauser. Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. Evidence-based Medicine. 20(1). (2015). 17. DOI: 10.1136\/ebmed-2014-110115.","DOI":"10.1136\/ebmed-2014-110115"},{"issue":"3","key":"10.1016\/j.prdoa.2022.100136_b0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1179\/1743291X12Y.0000000037","article-title":"Co-morbidities of persons dying of Parkinson's disease","volume":"21","author":"Lethbridge","year":"2013","journal-title":"Prog Palliat Care"},{"key":"10.1016\/j.prdoa.2022.100136_b0115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12883-018-1074-8","article-title":"Reduced gray matter volume and respiratory dysfunction in Parkinson\u2019s disease: a voxel-based morphometry study","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Neurol"}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259011252200007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259011252200007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:47:06Z","timestamp":1762912026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259011252200007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":23,"alternative-id":["S259011252200007X"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2022.100136","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parkinson\u2019s disease, treatment choice and survival over time","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2022.100136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100136"}}